- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Unresectable malignant mesothelioma
- Meeting Date: July 2024
- Public Summary Document (PSD) July 2024 PBAC Meeting - (PDF 396KB)
- Public Summary Document (PSD) July 2024 PBAC Meeting - (Word 73KB)
Nivolumab; ipilimumab – July 2024
Nivolumab; Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®; Ipilimumab; Injection concentrate for I.V. infusion 50 mg in 10 mL; Yervoy®
Last updated
30 May 2025
